BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, Wu JC, Chang FY, Lee SD. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol. 2001;32:240-244. [PMID: 11246354 DOI: 10.1097/00004836-200103000-00014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Wilfredo Canchis P, Gonzalez SA, Isabel Fiel M, Chiriboga L, Yee H, Edlin BR, Jacobson IM, Talal AH. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum α‐fetoprotein. Liver International 2004;24:198-203. [DOI: 10.1111/j.1478-3231.2004.00907.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
2 Huynh T, Hu KQ. Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma. Front Med 2019;13:658-66. [PMID: 31655955 DOI: 10.1007/s11684-019-0707-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein. Liver Int 2010;30:1161-8. [PMID: 20557454 DOI: 10.1111/j.1478-3231.2010.02301.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
4 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
5 Huynh T, Hu KQ. Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data. Dig Dis Sci 2021;66:1327-34. [PMID: 32405981 DOI: 10.1007/s10620-020-06286-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, Tawfik A. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. Eur J Gastroenterol Hepatol 2016;28:599-605. [PMID: 26741637 DOI: 10.1097/MEG.0000000000000569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
7 Kim CY, Kim BR, Lee SS, Jeon DH, Lee CM, Kim WS, Cho HC, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5844. [PMID: 28079817 DOI: 10.1097/MD.0000000000005844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
8 Kobeisy MA, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol. 2012;13:49-53. [PMID: 22980591 DOI: 10.1016/j.ajg.2012.06.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
9 Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013; 19(3): 339-346 [PMID: 23372355 DOI: 10.3748/wjg.v19.i3.339] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
10 Hussein YM, Morad FE, Gameel MA, Emam WA, El Sawy WH, El Tarhouny SA, Bayomy ES, Raafat N. MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.Med Oncol. 2012;29:3055-3062. [PMID: 22653756 DOI: 10.1007/s12032-012-0257-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
11 Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434-441. [PMID: 16136646 DOI: 10.1016/j.jhep.2005.03.019] [Cited by in Crossref: 208] [Cited by in F6Publishing: 195] [Article Influence: 12.2] [Reference Citation Analysis]
12 Zhang XF, Lai EC, Kang XY, Qian HH, Zhou YM, Shi LH, Shen F, Yang YF, Zhang Y, Lau WY, Wu MC, Yin ZF. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann Surg Oncol 2011;18:2218-23. [PMID: 21336512 DOI: 10.1245/s10434-011-1613-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
13 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol. 2012;84:1097-1105. [PMID: 22585728 DOI: 10.1002/jmv.23262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
14 Zhang XF, Yin ZF, Wang K, Zhang ZQ, Qian HH, Shi LH. Changes of serum alpha-fetoprotein and alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma: prognostic significance. Hepatobiliary Pancreat Dis Int. 2012;11:618-623. [PMID: 23232633 DOI: 10.1016/s1499-3872(12)60234-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
15 Khedr MA, Sira AM, Saber MA, Raia GY. Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response? Int J Hepatol 2015;2015:617623. [PMID: 26640716 DOI: 10.1155/2015/617623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Noritake H, Kobayashi Y, Ooba Y, Kitsugi K, Shimoyama S, Yamazaki S, Chida T, Watanabe S, Kawata K, Suda T. Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients. ISRN Hepatol 2014;2014:875140. [PMID: 27335844 DOI: 10.1155/2014/875140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci. 2010;55:3576-3583. [PMID: 20407827 DOI: 10.1007/s10620-010-1222-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
18 Enooku K, Nakagawa H, Soroida Y, Ohkawa R, Kageyama Y, Uranbileg B, Watanabe N, Tateishi R, Yoshida H, Koike K, Yatomi Y, Ikeda H. Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients: MtCK and hepatocarcinogenesis. Int J Cancer 2014;135:871-9. [DOI: 10.1002/ijc.28720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol. 2008;80:1354-1362. [PMID: 18551609 DOI: 10.1002/jmv.21202] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
20 Abdel-Razik A, Mousa N, Abdel-Aziz M, Elhelaly R, Elzehery R, Zalata K, Elkashef W, Fouda O, Awad M, Hafez M, Eldars W. Elevated serum α-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story. Eur J Gastroenterol Hepatol 2016;28:313-22. [PMID: 26618566 DOI: 10.1097/MEG.0000000000000534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012;55:231-241. [PMID: 21734353 DOI: 10.1159/000328327] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
22 Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Hematology/Oncology Clinics of North America 2003;17:625-46. [DOI: 10.1016/s0889-8588(03)00018-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Lee MH, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. Sci Rep. 2017;7:3718. [PMID: 28623331 DOI: 10.1038/s41598-017-02313-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
24 Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. J Med Virol. 2014;86:461-472. [PMID: 24166425 DOI: 10.1002/jmv.23824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
25 Chen J, Wu M, Gong J, Liu Z, He G, Zhu H, Li Z, Hu B. Influence of Alanine Transaminase Levels on Alpha-Fetoprotein for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Infection. Biomed Res Int 2020;2020:2043715. [PMID: 33490235 DOI: 10.1155/2020/2043715] [Reference Citation Analysis]
26 Mousa N, Gad Y, Abdel-Aziz A, Abd-Elaal I. Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4. Int J Hepatol 2012;2012:636392. [PMID: 22675639 DOI: 10.1155/2012/636392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
27 Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669-675. [PMID: 17444854 DOI: 10.1111/j.1440-1746.2007.04898.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
28 Yen C, Kuo Y, Wang J, Chang K, Kee K, Hung S, Chen Y, Tsai L, Chen S, Hung C, Lu S. Did AFP-L3 save ultrasonography in community screening? The Kaohsiung Journal of Medical Sciences 2018;34:583-7. [DOI: 10.1016/j.kjms.2018.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46:536-544. [PMID: 21132575 DOI: 10.1007/s00535-010-0349-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
30 Manuc D, Preda CM, Sandra I, Baicus C, Cerban R, Constantinescu I, Olteanu AO, Ciora CA, Manuc T, Chiriac DE, Chifulescu AE, Diculescu M, Tieranu C, Negreanu L, Oprea-Calin G, Manuc M. Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma. J Med Life 2020;13:68-74. [PMID: 32341704 DOI: 10.25122/jml-2019-0076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99:860-865. [PMID: 15128351 DOI: 10.1111/j.1572-0241.2004.04152.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 6.2] [Reference Citation Analysis]
32 Attallah AM, El-far M, Malak CAA, Omran MM, Farid K, Hussien MA, Albannan MS, Attallah AA, Elbendary MS, Elbesh DA, Elmenier NA, Abdallah MO. Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients. Annals of Hepatology 2015;14:225-33. [DOI: 10.1016/s1665-2681(19)30785-9] [Cited by in Crossref: 12] [Article Influence: 1.7] [Reference Citation Analysis]
33 Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol. 2014;86:131-138. [PMID: 24123090 DOI: 10.1002/jmv.23790] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
34 El Raziky M, Attia D, El Akel W, Shaker O, Khatab H, Abdo S, Elsharkawy A, Esmat G. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. Arab J Gastroenterol. 2013;14:94-98. [PMID: 24206736 DOI: 10.1016/j.ajg.2013.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kim H, Kim K, Jin J, Park J, Yu SJ, Yoon JH, Kim Y. Measurement of glycosylated alpha-fetoprotein improves diagnostic power over the native form in hepatocellular carcinoma. PLoS One 2014;9:e110366. [PMID: 25310463 DOI: 10.1371/journal.pone.0110366] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
36 Omran MM, Farid K, Emran TM, Attallah AA. Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol. 2011;12:74-79. [PMID: 21684477 DOI: 10.1016/j.ajg.2011.04.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
37 Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253-1262. [PMID: 23564522 DOI: 10.1002/hep.26442] [Cited by in Crossref: 155] [Cited by in F6Publishing: 151] [Article Influence: 17.2] [Reference Citation Analysis]
38 Tong MJ, Huynh TT, Siripongsakun S, Chang PW, Tong LT, Ha YP, Mena EA, Weissman MF. Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis. Hepatol Int 2015;9:567-77. [PMID: 26219830 DOI: 10.1007/s12072-015-9651-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
39 Fayed HM, Mahmoud HS, Elaiw Mohamed Ali A. The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals. Clin Exp Gastroenterol 2020;13:53-63. [PMID: 32110084 DOI: 10.2147/CEG.S229689] [Reference Citation Analysis]
40 Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, Yano K, Komori A, Migita K. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92-100. [PMID: 20711614 DOI: 10.1007/s00535-010-0293-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
41 Bongiovanni M, Ranieri R, Tincati C, Casana M, Marchetti G, Monforte AD. Serum α-Fetoprotein Levels Predict Early Virologic Response in HIV-Positive Subjects Treated for Chronic Hepatitis C. JAIDS Journal of Acquired Immune Deficiency Syndromes 2008;48:361-3. [DOI: 10.1097/qai.0b013e3181626fb8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Shehab-Eldeen S, Nada A, Abou-Elela D, El-Naidany S, Arafat E, Omar T. Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC). Asian Pac J Cancer Prev 2019;20:2515-22. [PMID: 31450927 DOI: 10.31557/APJCP.2019.20.8.2515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
43 Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229 [DOI: 10.3748/wjg.v28.i2.216] [Reference Citation Analysis]
44 Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S161-S172. [PMID: 12407590 DOI: 10.1053/jhep.2002.36989] [Cited by in Crossref: 36] [Cited by in F6Publishing: 65] [Article Influence: 1.8] [Reference Citation Analysis]
45 El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, ElAkel WA, Esmat G. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int. 2013;33:982-990. [PMID: 23509874 DOI: 10.1111/liv.12139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
46 Toson el-SA, Shiha GE, El-Mezayen HA, El-Sharkawy AM. Diagnostic performance of T lymphocyte subpopulations in assessment of liver fibrosis stages in hepatitis C virus patients: simple noninvasive score. Eur J Gastroenterol Hepatol 2016;28:931-9. [PMID: 27159125 DOI: 10.1097/MEG.0000000000000656] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
47 Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis. Am J Gastroenterology 2007;102:2196-205. [DOI: 10.1111/j.1572-0241.2007.01405.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
48 Said M. Evaluation of routine biochemical indices and α-fetoprotein versus histology in chronic hepatitis C patients. Arab Journal of Gastroenterology 2009;10:87-91. [DOI: 10.1016/j.ajg.2009.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
49 Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res. 2011;41:1036-1045. [PMID: 21883741 DOI: 10.1111/j.1872-034x.2011.00858.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
50 Clayton RF, Rinaldi A, Kandyba EE, Edward M, Willberg C, Klenerman P, Patel AH. Liver cell lines for the study of hepatocyte functions and immunological response. Liver Int 2005;25:389-402. [DOI: 10.1111/j.1478-3231.2005.01017.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
51 Wahb AMSE, El Kassas M, Khamis AK, Elhelbawy M, Elhelbawy N, Habieb MSE. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2021; 13(11): 1753-1765 [PMID: 34904043 DOI: 10.4254/wjh.v13.i11.1753] [Reference Citation Analysis]
52 Huang GQ, Zhu GQ, Huang S, You J, Shi KQ, Hu B, Ruan LY, Zhou MT, Braddock M, Zheng MH. Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. Expert Rev Gastroenterol Hepatol 2015;9:1127-38. [PMID: 26186642 DOI: 10.1586/17474124.2015.1057503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, Esmat G. Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon 2012;12:e6718. [PMID: 23346149 DOI: 10.5812/hepatmon.6718] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
54 Mohamed FZ, Hussein YM, El-deen IM, Sabea MS. Cyclooxygenase-2 single-nucleotide polymorphisms and hepatocellular carcinoma in Egypt. Mol Biol Rep 2014;41:1461-8. [DOI: 10.1007/s11033-013-2991-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
55 Hu CC, Weng CH, Hua MC, Chang PH, Lin CL, Chen YT, Chien CH, Lin ST, Chien RN. New Scoring Method to Predict Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C After Pegylated Interferon and Ribavirin Therapy. J Interferon Cytokine Res 2020;40:82-91. [PMID: 31800346 DOI: 10.1089/jir.2019.0103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S161-S172. [PMID: 12407590 DOI: 10.1002/hep.1840360721] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
57 Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am 2002;31:641-62. [PMID: 12134622 DOI: 10.1016/s0889-8553(02)00017-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
58 Abdelgawad ME, El-Zakzok H, Salah M, El-Mezayen HA. Diagnostic accuracy of hepatocyte growth factor, Fas/CD95 and Endostatin for non-invasive assessment of hepatic fibrosis in biopsy-proven hepatitis C virus patients. Infect Genet Evol 2020;85:104526. [PMID: 32890764 DOI: 10.1016/j.meegid.2020.104526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Carrat F, Bedossa P, Lunel-Fabiani F, Morand P, Pialoux G, Piroth L, Salmon-Céron D, Bani-Sadr F, Perronne C, Cacoub P. Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients. AIDS. 2008;22:1513-1515. [PMID: 18614875 DOI: 10.1097/qad.0b013e3282f7370d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Hu CC, Weng CH, Chang LC, Lin CL, Chen YT, Hu CF, Hua MC, Chen LW, Chien RN. Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy. Ther Clin Risk Manag 2018;14:783-91. [PMID: 29750037 DOI: 10.2147/TCRM.S158424] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol. 2014;49:555-563. [PMID: 24057163 DOI: 10.1007/s00535-013-0883-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
62 Kim KH, Lee SY, Kim DG, Lee S, Kim JY, Yoo JS. Absolute Quantification of N -Glycosylation of Alpha-Fetoprotein Using Parallel Reaction Monitoring with Stable Isotope-Labeled N -Glycopeptide as an Internal Standard. Anal Chem 2020;92:12588-95. [DOI: 10.1021/acs.analchem.0c02563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Tamura Y, Suda T, Arii S, Sata M, Moriyasu F, Imamura H, Kawasaki S, Izumi N, Takayama T, Kokudo N. Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci. 2013;58:2406-2412. [PMID: 23595518 DOI: 10.1007/s10620-013-2661-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
64 Albertoni G, Arnoni CP, Latini FR, Andrade SS, Araújo PR, Rodrigues FK, Rozenchan PB, Mendes-Correa MC, Leite OH, Schor N, Girão MJ, Barreto JA. Altered of apoptotic markers of both extrinsic and intrinsic pathways induced by hepatitis C virus infection in peripheral blood mononuclear cells. Virol J 2012;9:314. [PMID: 23256595 DOI: 10.1186/1743-422X-9-314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
65 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79:1686-1695. [PMID: 17854035 DOI: 10.1002/jmv.20979] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.5] [Reference Citation Analysis]
66 Saad Y, Awad A, Alakel W, Doss W, Awad T, Mabrouk M. Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients. Eur J Gastroenterol Hepatol 2018;30:201-6. [PMID: 29099423 DOI: 10.1097/MEG.0000000000001008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS, Lee CM. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc 2009;108:210-8. [PMID: 19293036 DOI: 10.1016/S0929-6646(09)60054-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
68 Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, Deubner H, Williams J, Livingston SE, Gretch D. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. J Viral Hepat 2008;15:179-87. [PMID: 18233991 DOI: 10.1111/j.1365-2893.2007.00928.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
69 Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients: Elderly HCV-associated HCC patients. J Gastroenterol Hepatol 2013;28:357-64. [DOI: 10.1111/jgh.12057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
70 Musch E, Malek M, von Eick H, Chrissafidou A. Successful Long-term Application of Highly Purified Natural Interferon-alpha (Multiferon®) after Preceding Interferon Approaches in a Chronic Hepatitis C Patient with Thrombocytopenia. Scandinavian Journal of Infectious Diseases 2009;36:395-9. [DOI: 10.1080/00365540410019561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
71 Tamura Y, Yamagiwa S, Aoki Y, Kurita S, Suda T, Ohkoshi S, Nomoto M, Aoyagi Y. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci. 2009;54:2530-2537. [PMID: 19093203 DOI: 10.1007/s10620-008-0642-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
72 Badawi R, Alboraie M, Abd-Elsalam S, Abourahma MZ, Ramadan HK, Ahmed OA, Fouad MHA, Soliman S, Mohareb DA, Haydara T, Alnabawy SM, El Kassas M. Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt. Endocr Metab Immune Disord Drug Targets 2019;19:1005-11. [PMID: 30727931 DOI: 10.2174/1871530319666190204154830] [Reference Citation Analysis]